Cornerstone Investment Partners LLC Has $87.75 Million Holdings in Cencora, Inc. $COR

Cornerstone Investment Partners LLC lowered its position in shares of Cencora, Inc. (NYSE:COR) by 15.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 292,637 shares of the company’s stock after selling 53,692 shares during the period. Cencora accounts for about 3.9% of Cornerstone Investment Partners LLC’s holdings, making the stock its 7th biggest position. Cornerstone Investment Partners LLC owned 0.15% of Cencora worth $87,747,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Atlantic Edge Private Wealth Management LLC grew its position in shares of Cencora by 70.0% during the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after purchasing an additional 35 shares in the last quarter. Cornerstone Planning Group LLC raised its position in shares of Cencora by 106.7% in the first quarter. Cornerstone Planning Group LLC now owns 93 shares of the company’s stock worth $26,000 after buying an additional 48 shares in the last quarter. Costello Asset Management INC bought a new stake in Cencora during the first quarter valued at $28,000. University of Texas Texas AM Investment Management Co. bought a new stake in Cencora during the first quarter valued at $39,000. Finally, Caitong International Asset Management Co. Ltd purchased a new position in Cencora during the second quarter worth about $61,000. Institutional investors own 97.52% of the company’s stock.

Cencora Stock Performance

NYSE:COR opened at $360.29 on Friday. The business has a 50 day moving average of $312.89 and a 200 day moving average of $298.79. The company has a market capitalization of $69.85 billion, a price-to-earnings ratio of 37.07, a PEG ratio of 1.56 and a beta of 0.63. Cencora, Inc. has a 1-year low of $223.92 and a 1-year high of $362.00. The company has a debt-to-equity ratio of 3.64, a current ratio of 0.90 and a quick ratio of 0.53.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, beating analysts’ consensus estimates of $3.79 by $0.05. The business had revenue of $83.73 billion for the quarter, compared to analysts’ expectations of $83.36 billion. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The business’s quarterly revenue was up 5.9% on a year-over-year basis. During the same period last year, the business earned $3.34 earnings per share. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, sell-side analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 14th will be given a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Friday, November 14th. This is a boost from Cencora’s previous quarterly dividend of $0.55. Cencora’s dividend payout ratio is 22.63%.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Cencora in a report on Thursday, October 30th. Evercore ISI set a $400.00 price objective on Cencora and gave the stock an “outperform” rating in a report on Thursday. Wall Street Zen downgraded shares of Cencora from a “buy” rating to a “hold” rating in a research note on Saturday, October 11th. Mizuho lifted their target price on shares of Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a research report on Thursday. Finally, Robert W. Baird increased their price target on shares of Cencora from $355.00 to $395.00 and gave the stock an “outperform” rating in a report on Thursday. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $348.00.

Insider Buying and Selling at Cencora

In other news, CEO Robert P. Mauch sold 5,097 shares of Cencora stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $326.80, for a total value of $1,665,699.60. Following the transaction, the chief executive officer owned 37,940 shares in the company, valued at approximately $12,398,792. The trade was a 11.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Chairman Steven H. Collis sold 31,350 shares of the stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total value of $9,087,111.00. Following the sale, the chairman owned 305,913 shares of the company’s stock, valued at $88,671,942.18. This represents a 9.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 41,544 shares of company stock valued at $12,230,941 over the last three months. 10.80% of the stock is currently owned by insiders.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.